Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand and have the ability to provide written consent~* Between 18 and 70 years of age~* Patients with CD33 positive (determined as CD33 expression in ≥ 20% of leukemic blasts) de novo AML that did not respond to first line induction therapy~* ECOG Performance Status of 0-2~* Patients must have the following laboratory values within 48 hours prior to beginning protocol treatment: Serum creatinine ≤ 1.5 mg/ml and calculated creatinine clearance ≥ 50mL/min (using the Cockcroft-Gault equation); AST ≤ 59 IU/L; ALT ≤ 72 IU/L; Total bilirubin ≤ 1.3 mg/ml; Note: Hematologic abnormalities will not be used as a criteria for entry or exclusion.~* Patients must have left ventricular ejection fraction (LVEF) ≥50%~* Females of child-bearing potential must have a negative pregnancy test during screening and all subjects must agree to use an effective method of contraception.~Exclusion Criteria:~* Patients with acute promyelocytic leukemia~* Prior use of mitoxantrone or etoposide or gemtuzumab ozogamicin~* Antecedent hematologic disorder preceding initial presentation of AML or therapy related AML~* History of thromboembolic event within the past 12 months~* Hepatitis B or C or HIV positive serology~* Symptomatic central nervous system (CNS) involvement~* History of congestive heart failure~* Myocardial infarction in the past 6 months~* Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy~* History of psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consent~* Patient may not be receiving any other anti neoplastic investigational agents~* INR\> 1.5 or patient is receiving systemic anticoagulation (e.g warfarin)~* Patient undergone autologous or allogeneic stem cell transplantation~* Other active malignancies except for non-melanoma skin cancer or cervical intraepithelial neoplasia~* Women who are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Gemtuzumab ozogamicin/Mitoxantrone/Etoposide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).